Vergoeding 2020-2024 voor ATC-subgroep L04AG : Monoklonale antilichamen
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| L04AG03 Natalizumab | 20.488.772 | 18.954.158 | 18.302.935 | 17.635.118 | 14.970.736 |
| L04AG04 Belimumab | 1.388.282 | 1.953.029 | 2.321.440 | 2.826.392 | 3.362.216 |
| L04AG05 Vedolizumab | 42.596.426 | 50.204.262 | 55.427.788 | 63.278.791 | 69.904.061 |
| L04AG06 Alemtuzumab | 1.165.468 | 1.414.602 | 1.397.014 | 1.140.460 | 519.663 |
| L04AG08 Ocrelizumab | 31.722.793 | 45.874.148 | 60.735.720 | 73.424.179 | 88.074.742 |
| L04AG11 Anifrolumab | . | . | 7.814 | 200.178 | 395.464 |
| Totaal | 97.361.742 | 118.400.199 | 138.192.710 | 158.505.118 | 177.226.881 |